Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
40 Results for "
PCSK9 protein
" in MedChemExpress (MCE) Product Catalog:
Products (40)
40 Results for "PCSK9 protein" in MCE Product Catalog:
3
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
1
1 Cited Publications
Cat. No.: HY-W510159
CAS No.: 56005-10-8
Target:
1
1 Cited Publications
Target:
Research Areas:
PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC50 of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research .
1
1 Cited Publications
Cat. No.: HY-P73340
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PCSK9; PC9; Prev. HCHOLA3; Hypercholesterolemia, Autosomal Dominant 3; NARC-1; Neural Apoptosis Regulated Convertase 1; Subtilisin/Kexin-Like Protease PC9; Neural Apoptosis-Regulated Convertase 1; FH3; LDLCQ1; Proprotein Convertase 9; FHCL3; NARC1; Propro
Species:
Rat
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P73728
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PCSK9; PC9; Prev. HCHOLA3; Hypercholesterolemia, Autosomal Dominant 3; NARC-1; Neural Apoptosis Regulated Convertase 1; Subtilisin/Kexin-Like Protease PC9; Neural Apoptosis-Regulated Convertase 1; FH3; LDLCQ1; Proprotein Convertase 9; FHCL3; NARC1; Propro
Species:
Human
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P71189A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PCSK9; PC9; Prev. HCHOLA3; Hypercholesterolemia, Autosomal Dominant 3; NARC-1; Neural Apoptosis Regulated Convertase 1; Subtilisin/Kexin-Like Protease PC9; Neural Apoptosis-Regulated Convertase 1; FH3; LDLCQ1; Proprotein Convertase 9; FHCL3; NARC1; Propro
Species:
Mouse
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P70545A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PCSK9; PC9; Prev. HCHOLA3; Hypercholesterolemia, Autosomal Dominant 3; NARC-1; Neural Apoptosis Regulated Convertase 1; Subtilisin/Kexin-Like Protease PC9; Neural Apoptosis-Regulated Convertase 1; FH3; LDLCQ1; Proprotein Convertase 9; FHCL3; NARC1; Proprotein Convertase Subtilisin/Kexin Type 9; Convertase Subtilisin/Kexin Type 9 Preproprotein
Species:
Human
Source:
HEK293
Target:
Research Areas:
PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .
Cat. No.: HY-162562
CAS No.: 930017-01-9
Target:
Research Areas:
E28362 is an orally active lipid-lowering agent and a selective PCSK9 antagonist. E28362 blocks the interaction between PCSK9 and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis .
Cat. No.: HY-130245
Purity: 98.33%
Research Areas:
PCSK9 degrader 1 is a HyT-like PCSK9 degrader with a Ki of 107 nM. PCSK9 degrader 1 binds to the allosteric pocket between the catalytic domain and C-terminal domain of PCSK9. While maintaining key interactions with this protein, it extends the proteasome-recruiting moiety, thereby driving degradation via the proteasomal pathway. PCSK9 degrader 1 induces the degradation of both the precursor and mature forms of PCSK9, with DC50 values of 4.8 μM and 3.4 μM respectively, and does not significantly affect cell viability or the expression of housekeeping proteins. PCSK9 degrader 1 can be used in the research of coronary heart disease .
Cat. No.: HY-163794
CAS No.: 2135765-21-6
Research Areas:
DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia .
Cat. No.: HY-158827A
Target:
Research Areas:
AZD8233 sodium, a liver-targeting antisense oligonucleotide (ASO), inhibits subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 sodium increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.
Cat. No.: HY-149310
CAS No.: 2743448-32-8
Target:
Research Areas:
Dim16 is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC50 of 0.8 nM against human PCSK9 and an IC50 of 146.8 μM against HMG-CoAR. Dim16 disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 can be used in research related to hypercholesterolemia .
Cat. No.: HY-P99696
CAS No.: 2250073-78-8
Synonyms: LIB003
Target:
Research Areas:
Cat. No.: HY-146084
CAS No.: 2476490-18-1
Target:
Research Areas:
PCSK9 modulator-3 is a PCSK9 modulator that reduces the secretion level of PCSK9 protein in HepG2 cells. PCSK9 modulator-3 exhibits metabolic stability in liver microsomes of mice and rats. PCSK9 modulator-3 can be used for the study of hyperlipidemia .
Cat. No.: HY-17640
CAS No.: 1269181-69-2
Target:
Research Areas:
Nicodicosapent is a fatty acid niacin conjugate that is also an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.
Cat. No.: HY-159595
CAS No.: 1233353-86-0
Research Areas:
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
Cat. No.: HY-160036
CAS No.: 2794203-47-5
Target:
Research Areas:
PCSK9-IN-22 (compound 29) is an orally active inhibitor of PCSK9. PCSK9-IN-22 inhibits the interaction of the protein with LDLR in vivo .
Cat. No.: HY-158827
CAS No.: 2604215-74-7
Target:
Research Areas:
AZD8233, a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.
Cat. No.: HY-155415
CAS No.: 2929219-77-0
Target:
Research Areas:
PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor with an IC50 of 3.96 µM. PCSK9-IN-20 decreases PCSK9 and increases LDLR protein expression in vitro .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
